**The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Item No.** | **STROBE items** | **Location in manuscript where items are reported** | **RECORD items** | **Location in manuscript where items are reported** |
| **Title and abstract** | | | | | |
|  | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Title and Abstract | RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.  RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.  RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract. | Title and Abstract  Title and Abstract  Not applicable |
| **Introduction** | | | | | |
| Background rationale | 2 | Explain the scientific background and rationale for the investigation being reported | The 1st paragraph of the INTRODUCTION (page 7) |  |  |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Last 2 sentences of the 1st paragraph and 2nd paragraph of the INTRODUCTION (page 7−8) |  |  |
| **Methods** | | | | | |
| Study Design | 4 | Present key elements of study design early in the paper | The 1st sentence of *Study design and data source* subsection of the MATERIALS AND METHODS (page 8) |  |  |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | *Study design and data source* subsection of the MATERIALS AND METHODS (page 8) |  |  |
| Participants | 6 | *(a) Cohort study* - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  *Case-control study* - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  *Cross-sectional study* - Give the eligibility criteria, and the sources and methods of selection of participants  *(b) Cohort study* - For matched studies, give matching criteria and number of exposed and unexposed  *Case-control study* - For matched studies, give matching criteria and the number of controls per case | *Study design and data source* subsection and *Patients* subsection of the MATERIALS AND METHODS (page 8), and Supplementary Table 1 (supplementary material)  The 4th paragraph of *Outcomes and analysis* subsection of the MATERIALS AND METHODS (page 10) | RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.  RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.  RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage. | *Patients* subsection of the MATERIALS AND METHODS (page 8), and Supplementary Table 1 (supplementary material)  Not applicable  Not applicable |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | *Outcomes and analysis* subsection of the MATERIALS AND METHODS (pages 8− 11), and Supplementary Tables 2 and 3 (supplementary material) | RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided. | 1st paragraph of *Outcomes and analysis* subsection of the MATERIALS AND METHODS (pages 8−9), and Supplementary Tables 2 and 3 (supplementary material) |
| Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement).  Describe comparability of assessment methods if there is more than one group | The last paragraph of the INTRODUCTION (pages 7−8) and *Study design and data source* subsection of the MATERIALS AND METHODS (page 8) |  |  |
| Bias | 9 | Describe any efforts to address potential sources of bias | The 3rd and 4th paragraph of *Outcomes and analysis* subsection of the MATERIALS AND METHODS (pages 9−10) and the *Limits of the study* subsection of the DISCUSSION (page 18) |  |  |
| Study size | 10 | Explain how the study size was arrived at | Not applicable (all eligible patients in the database were included) |  |  |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why | *Outcomes and analysis* subsection of the MATERIALS AND METHODS (pages 8−11) |  |  |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding  (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) *Cohort study* - If applicable, explain how loss to follow-up was addressed  *Case-control study* - If applicable, explain how matching of cases and controls was addressed  *Cross-sectional study* - If applicable, describe analytical methods taking account of sampling strategy  (e) Describe any sensitivity analyses | *Outcomes and analysis* subsection of the MATERIALS AND METHODS (pages 8−11) |  |  |
| Data access and cleaning methods |  | .. |  | RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.  RECORD 12.2: Authors should provide information on the data cleaning methods used in the study. | The 2nd paragraph of the INTRODUCTION (pages 7−8)  Not applicable |
| Linkage |  | .. |  | RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided. | Not applicable |
| **Results** | | | | | |
| Participants | 13 | (a) Report the numbers of individuals at each stage of the study (*e.g.*, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed)  (b) Give reasons for non-participation at each stage.  (c) Consider use of a flow diagram | 1st paragraph of *Overview of disease developments* subsection (page 11), 2nd paragraph of *GERD* subsection (page 12), 1st paragraph of *Changes in BMI and MS* subsection (page 13), and Figure 2 | RECORD 13.1: Describe in detail the selection of the persons included in the study (*i.e.,* study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram. | 1st paragraph of *Overview of disease developments* subsection (page 11), 2nd paragraph of *GERD* subsection (page 12), 1st paragraph of *Changes in BMI and MS* subsection (page 13), and Figure 2 |
| Descriptive data | 14 | (a) Give characteristics of study participants (*e.g.*, demographic, clinical, social) and information on exposures and potential confounders  (b) Indicate the number of participants with missing data for each variable of interest  (c) *Cohort study* - summarise follow-up time (*e.g.*, average and total amount) | 1st paragraph of *Overview of disease developments* subsection (page 11), and Figures 1 and 2 |  |  |
| Outcome data | 15 | *Cohort study* - Report numbers of outcome events or summary measures over time  *Case-control study* - Report numbers in each exposure category, or summary measures of exposure  *Cross-sectional study* - Report numbers of outcome events or summary measures | Figure 2 and Supplementary Figures 4 and 5 (supplementary material) |  |  |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included  (b) Report category boundaries when continuous variables were categorized  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Figure 2 |  |  |
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Figures 3A, 4A, 5, and 6A, and Supplementary Figure 3A (supplementary material) |  |  |
| **Discussion** | | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | The 1st sentence of the 2nd−4th, paragraph, last sentence of the 5th paragraph, 4th sentence of the 6th paragraph of the DISCUSSION (pages 14−17). |  |  |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | *Limits of the study* subsection of the DISCUSSION (page 18) | RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported. | *Limits of the study* subsection of the DISCUSSION (page 18) |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | The 2nd−8th paragraph of the DISCUSSION (pages 14−18) |  |  |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Last 3 sentences in the *Limits of the study* subsection of the DISCUSSION (page 18) |  |  |
| **Other Information** | | | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Not applicable |  |  |
| Accessibility of protocol, raw data, and programming code |  | .. |  | RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code. | Data sharing statement section (page 2) |

\*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

\*Checklist is protected under Creative Commons Attribution ([CC BY](http://creativecommons.org/licenses/by/4.0/)) license.